The USFDA has completed an inspection of the facility of Granules Pharmaceuticals, Inc., a wholly-owned foreign subsidiary of Granules India located in Chantilly, Virginia, the USA on July 22, 2022 with six observations. Granules Pharmaceuticals, Inc. will respond to these observations within the stipulated time period.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
